Integrated Pharma Firm Syngene Hits Rs. 496.2 Crore Profit

Syngene International has made a report stating that it has earned a total income of Rs.1036.9 for the period ended March 31, 2025. Leading to the company making a net profit of 183.3 crores for the same period. The company's financial year 2025 earnings have been recorded to be Rs.3,714.2 crores compared to the financial year 2024 earnings of Rs. 3,573.2 crores.

This has made the company’s net profit for the year 2025 to be Rs.496.2 crores on March 31, 2025. In response to the finance report, The Managing director and CEO of Syngene International Limited stated, “Syngene reported revenue growth of 11 percent  year-on-year and 8 percent sequentially, crossing the Rs. 1,000 Cr. in a quarter threshold for the first time. At the EBITDA level, growth was 9 percent year-on-year, reflecting good underlying fundamentals. The full-year results, led by reported revenue growth of 4 percent, are in line with our January guidance, reflecting a resilient performance in a challenging year. After a muted first half, driven by a sectoral downturn in US biotech funding, we are encouraged to see a return to growth in the second half of the year. At the EBITDA level, growth was 9 percent year-on-year, reflecting good underlying fundamentals. The highlight of the quarter was the acquisition of a state-of-the-art biologics manufacturing facility in the US, strengthening Syngene’s position in the fast-growing biologics CDMO sector and providing a strategic foothold in the US market.”

The company says its growth increased in the 4th quarter. The company had more strategic investments. This resulted in the enhancement of the company’s capabilities and capacities among various sectors across research, development, and manufacturing services. The company also focused on reducing the operational cost by increasing the operational efficiencies. Deepak Jain, Chief Financial Officer, Syngene International Limited, commented, “Looking ahead into the next financial year, we expect the momentum to continue, with reported revenue growth at the mid-single-digit level. As we bring the new biologics manufacturing facilities into operation, the additional operating costs and depreciation will impact margins. With this, we expect EBITDA margin to moderate from current levels to the mid-twenties and year-on-year decline in profit after tax.”